Table 1.

Demographic and clinical characteristics of patients with controlled severe asthma (CSA) and uncontrolled severe asthma (UCSA).

	Total	CSA	UCSA	P
	M (Q1-Q3)	M (Q1-Q3)	M (Q1-Q3)
Age	55.5 (44.6–64.4)	55.5 (49.25–64.3)	57.5 (44.8–63.34)	0.74
BMI (kg/m2)	28.9 (25.7–32.5)	27.8 (25.7–31.3)	30.7 (25.6–33.8)	0.3
2018	n = 60	n = 37	n = 23
RR	17 (16–18)	16 (16–18.5)	18 (16.18)	0.36
HR (bpm)	76 (70–80)	75 (70–80)	76 (72–80)	0.26
2019	n = 60	n = 38	n = 22
RR	16 (16–18)	16 (16–18)	17 (16–18)	0.26
HR	72 (70.0–75.7)	71.5 (70.0–75.0)	73 (67.8–77.5)	0.74
2018	n = 40	n = 23	n = 17
FEV1 (%)	80.0 (68.3–91.8)	87.0 (71.0–93.0)	73.0 (59.50–82.50)	0.08
PEF (%)	88.0 (70.5–107.3)	102.0 (82.0–113.0)	76.0 (64.50–92.50)	0.005
	n = 12	n = 6	n = 6
IgE (mg/dL)	606 (232–2153)	606 (324–2568)	730 (193–2863)	0.7
	n = 22	n = 15	n = 7
Leukocytes, thousands/μL	6628 (8405–10245)	6530 (8370–9200)	6660 (10,080–11150)	0.36
Eosinophils, thousands/μL	175 (430.0–648.5)	160 (330.0–650.0)	260 (460–648)	0.6
Eosinophils ˃300, thousands/μL, n (%)	14 (63.6)	8 (53.3)	5 (71.4)
2019	n = 40	n = 23	n = 17
FEV1	83.0 (68.0–90.8)	83.0 (68.0–93.0)	83.0 (67.5–89.0)	0.58
PEF	92.0 (80.0–105.5)	92.0 (82.0–109.0)	93.0 (79.5–104.0)	0.68
	n = 16	n = 10	n = 6
IgE	250 (172.0–440)	280 (131–490)	221 (160–502.5)	0.98
	n = 24	n = 14	n = 10
Leukocytes	8505 (5725–10090)	8640 (5688–10338)	8190 (5698–10198)	0.83
Eosinophils	371 (205–565)	371 (258–693)	355 (168–468)	0.34
Eosinophils ˃ 300, n (%)	14 (58.3)	9 (64.3)	5 (50.0)

UCSA was defined by the presence of at least one exacerbation in the year; BMI, body mass index; RR, respiratory rate; HR, heart rate; P, p-value resulting from the Mann-Whitney test; Q1 and Q3, quartiles 1 and 3 respectively